A Novel Bcma-Specific, Centyrin-Based CAR-T Product for the Treatment of Multiple Myeloma

被引：17
|
作者：
Hermanson, David L. [1 ]
Barnett, Burton Earle [1 ]
Rengarajan, Srinivas [1 ]
Codde, Rebecca [1 ]
Wang, Xinxin [1 ]
Tan, Yening [1 ]
Martin, Christopher E. [1 ]
Smith, Jenessa Barbara [1 ]
He, Jin [2 ]
Mathur, Rohit [3 ]
Yan, Jing
Neelapu, Sattva S. [4 ]
Osertag, Eric M. [1 ]
Shedlock, Devon J. [1 ]
机构：
[1] Poseida Therapeut, San Diego, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
[3] MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2127.2127
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2127
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
    Golubovskaya, Vita
    Zhou, Hua
    Li, Feng
    Berahovich, Robert
    Sun, Jinying
    Valentine, Michael
    Xu, Shirley
    Harto, Hizkia
    Sienkiewicz, John
    Huang, Yanwei
    Wu, Lijun
    BIOMEDICINES, 2021, 9 (10)
  • [22] γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
    Pont, Margot J.
    Hill, Tyler
    Cole, Gabriel O.
    Abbott, Joe J.
    Kelliher, Jessica
    Salter, Alexander I.
    Hudecek, Michael
    Comstock, Melissa L.
    Rajan, Anusha
    Patel, Bharvin K. R.
    Voutsinas, Jenna M.
    Wu, Qian
    Liu, Lingfeng
    Cowan, Andrew J.
    Wood, Brent L.
    Green, Damian J.
    Riddell, Stanley R.
    BLOOD, 2019, 134 (19) : 1585 - 1597
  • [23] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [24] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
    Zhang, Xiaohui
    Ouyang, Chenxi
    Sun, Guofeng
    Liu, Hongfeng
    Qi, Junyuan
    Suo, Xiaohui
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
  • [25] Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma.
    Fan, Frank
    Zhao, Wanhong
    Liu, Jie
    He, Aili
    Chen, Yinxia
    Cao, Xingmei
    Yang, Nan
    Wang, Baiyan
    Zhang, Pengyu
    Zhang, Yilin
    Wang, Fangxia
    Lei, Bo
    Gu, Liufang
    Wang, Xugeng
    Zhuang, Qiuchuan
    Zhang, Wanggang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] BCMA CAR-T cells in multiple myeloma-ready for take-off?
    Scheller, Lukas
    Tebuka, Erius
    Rambau, Peter Fabian
    Einsele, Hermann
    Hudecek, Michael
    Prommersberger, Sabrina Rebecca
    Danhof, Sophia
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 143 - 157
  • [27] Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma
    Reyes, Kevin R.
    Huang, Chiung-Yu
    Lo, Mimi
    Arora, Shagun
    Chung, Alfred
    Wong, Sandy W.
    Wolf, Jeffrey
    Olin, Rebecca L.
    Martin, Thomas
    Shah, Nina
    Banerjee, Rahul
    TRANSPLANTATION AND CELLULAR THERAPY, 2023, 29 (06): : 350 - 355
  • [28] A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
    Zhang, Hua
    Gao, Lei
    Liu, Li
    Wang, Jishi
    Wang, Sanbin
    Gao, Li
    Zhang, Cheng
    Liu, Yao
    Kong, Peiyan
    Liu, Jia
    He, Jiaping
    Han, Yu
    Shi, Hua
    He, Yan
    Ye, Xun
    Zhao, Yi
    Cao, Wei
    Shen, Lianjun
    Zhang, Xi
    BLOOD, 2019, 134
  • [29] Pseudoprogression in multiple myeloma patients treated with Anti-BCMA CAR-T cells
    Topp, Max
    Schimanski, Sven
    Hornburger, Hannah
    Kadel, Sophie
    Einsele, Hermann
    Rasche, Leo
    Duell, Johannes
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 146 - 146
  • [30] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
12345